ELVN
Enliven Therapeutics Inc.
42.40$
-6.8%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -1.3% | +2.6% | -1.3% | +2.6% | +0.0% | -7.5% | +108.1% | -59.7% | +62.9% | +177.2% | -97.5% | – | |
| – | -10.1% | +47.7% | +13.9% | +0.6% | +3.1% | +27.3% | +13.6% | -7.0% | +71.3% | -39.9% | +88.1% | – | |
| – | +73.4% | -184.8% | – | – | -110.2% | – | – | -150.2% | – | -381.7% | – | – | |
| – | -12.5% | +42.9% | -90.0% | +1,000.0% | -100.0% | – | +595.0% | -99.3% | -100.0% | – | – | – | |
| – | – | -146.2% | +88.2% | – | -95.1% | +96.3% | -12,965.4% | -97.8% | – | +243.5% | -1,138.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | +100,200.0% | -98.0% | -38.2% | +3,478.5% | -99.4% | +93,223.9% | -100.2% | – | +1,513.6% | +4,509.7% | – | |
| – | – | +86.1% | -206.7% | – | +526.6% | -195.6% | – | -199.8% | – | – | -90.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.